Business & Finance
BIOCORP swings to net profit of EUR294.2000 in 2021
6 April 2022 -

French medical device company BIOCORP (Paris:ALCOR) reported on Tuesday its net profit of EUR294.2000 for the year ended on 31 December 2021.

This marks an improvement when compared with net loss of EUR1.242m in 2020.

Annual revenues of EUR10.23m were generated in 2021, a growth of 20.9% over the annual revenues of EUR8.46m in 2020 following the invoicing of services provided for in Merck and Novo Nordisk contracts.

Operating expenses of EUR10.42m was recorded in 2021, up 3.3% versus EUR10.08m 2020, demonstrating good control of operating expenses.

For 2022, the company expects continued development of new generations of Mallya products for industrial partners and continued expansion of its applications beyond diabetes, a target of 50,000 Mallya manufactured products, to launch new connected devices in the field of injection, growth investments in software and cloud to generate revenues as well as strengthen the team with ten new recruitments.



Related Headlines